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The number of depressed patients treated with deep brain stimulation (DBS) is relatively
small. However, experience with this intervention now spans more than 10 years
at some centers, with study subjects typically monitored closely. Here we describe
one center’s evolving impressions regarding optimal patient selection for DBS of the
subcallosal cingulate (SCC) as well as observations of short- and long-term patterns in
antidepressant response and mood reactivity. A consistent time course of therapeutic
response with distinct behavioral phases is observed. Early phases are characterized
by changes in mood reactivity and a transient and predictable worsening in self ratings
prior to stabilization of response. It is hypothesized that this characteristic recovery curve
reflects the timeline of neuroplasticity in response to DBS. Further investigation of these
emerging predictable psychiatric, biological, and psychosocial patterns will both improve
treatment optimization and enhance understanding and recognition of meaningful DBS
antidepressant effects.
Keywords: treatment resistant depression, deep brain stimulation, subcallosal cingulate, therapeutic course,
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Introduction
Deep brain stimulation (DBS) is being investigated as a potential therapy for treatment-resistant
depression (TRD). The DBS target with the most experience is the subcallosal cingulate
white matter, alternatively referred to as subgenual or Area 25 DBS (SCC; Mayberg et al.,
2005; Lozano et al., 2008, 2012; Bewernick et al., 2010; Kennedy et al., 2011; Holtzheimer
et al., 2012; Puigdemont et al., 2012; Merkl et al., 2013; Ramasubbu et al., 2013). Therapeutic
response has also been reported with DBS of the nucleus accumbens (NAC)/medial forebrain
bundle (MFB; Schlaepfer et al., 2008, 2013; Bewernick et al., 2010, 2012), and ventral
capsule/ventral striatum (VC/VS; Malone et al., 2009; Dougherty et al., 2014). While studies
of DBS at these targets vary in design and rationale, small trials have demonstrated
clear benefit, including long-term sustained antidepressant response (Kennedy et al., 2011;
Bewernick et al., 2012; Holtzheimer et al., 2012). However, pivotal industry-sponsored
trials have not demonstrated efficacy (Dougherty et al., 2014; closure of the BROADEN
trial).1 For DBS to be validated as a reliable treatment strategy for depression, each
1http://www.sjm.com/broaden
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independent approach must clearly define the precise
surgical target, appropriate patient selection, time course
of antidepressant response, and symptom specificity of that
response. Given the small number of researchers with firsthand
experience with DBS for depression, open dialog tomaximize our
collective experiential knowledge of this treatment is encouraged.
Towards this goal, we offer a single lab perspective (Emory
University, Atlanta GA, USA) from 8 years of studies of SCC
DBS for TRD, highlighting the key clinical features of patient
selection and the DBS-mediated therapeutic response in this
target (Table 1; clinicaltrials.gov NCT00367003, NCT01984710).
Patients
Screening and evaluating hundreds of participants with in-
depth assessments (Table 1) has shaped our view that three
factors characterize a DBS responsive patient: (1) history of
clear antidepressant response in early depressive episodes with
evidence of inter-episode functional recovery (job, family,
activities); (2) transformation from treatment-responsive to
treatment-resistant depression; and (3) lack of emotional
reactivity at presentation.
A typical history for those participants who respond to DBS
starts with a depressive episode in their 20s that responded
to antidepressant medication with symptomatic and functional
recovery. In subsequent episodes, more aggressive antidepressant
treatment was required and more medication failures were
experienced. Most underwent electroconvulsive therapy, with
an initial good response that could not be recaptured when
symptoms later returned. Puigdemont et al. (2012) reported a
similar pattern of disease progression. Patients’ descriptions of
their depression often include themes of psychic pain, darkness,
being weighted down, or being in a hole. This is accompanied
by pronounced psychomotor slowing, non-fluent, monotonous
speech, and limited affective range. Consequently, these qualities
have taken on the most weight in our assessments of potential
new subjects.
All subjects must meet a minimum severity score on a
standardized rating scale for study inclusion (Table 1). However,
disease severity cannot be solely defined this way. While a
severity score on a depression rating scale can be informative
and is important for research metrics and study integrity,
assumptions about severity scores may be a confound in this
chronically ill population (Bech et al., 1975; Snaith, 1977; Bagby
et al., 2004). Chronicity, treatment resistance, and functional
impairment define overall disease severity in addition to total
symptom burden.
DBS Lead Placement
Intraoperative testing of DBS contacts is conducted in awake
subjects to explore acute stimulation effects, assess safety,
and confirm electrode placement. In the SCC target, acute
effects to stimulation including ‘‘lightness’’ and ‘‘connectedness’’
were initially reported and replicated in subsequent studies
(Mayberg et al., 2005; Lozano et al., 2008; Holtzheimer et al.,
2012; Merkl et al., 2013), but are not universal (Puigdemont
et al., 2012; Ramasubbu et al., 2013). Our subjects have
not experienced adverse events during intraoperative testing,
although stimulation of many contacts produce no discernable
behavioral effects. While the experiences reported by patients
are highly personal and thus idiosyncratic, the predominant
characteristic is relief from negative rather than induction of
positive mood. Return of negative mood is noted soon after
discontinuation of the stimulation. Acute behavioral phenomena
to stimulation have been reported at other DBS targets and
generally fall into categories of decreased negative mood;
increased positive mood, interest, and motivation; autonomic
changes including increased heart rate, sweating, or flushing;
and unpleasant sensations of anxiety and mental or physical
slowing (Mayberg et al., 2005; Lozano et al., 2008; Schlaepfer
et al., 2008, 2013; Malone et al., 2009; Bewernick et al., 2010;
Holtzheimer et al., 2012; Merkl et al., 2013; Riva-Posse et al.,
2014a). Possible explanations of these phenomena include:
site-specific behavioral biomarkers of antidepressant response,
epiphenomena that may or may not have clinical relevance, or
simply side effects of the spread of electric current to adjacent
structures. In some cases, as in double vision with stimulation
of the MFB (Schlaepfer et al., 2013), the specificity, predictability
(based on local anatomy), and reproducibility of the effect would
point toward this being a side effect. In contrast, smiling has
been reported as asymmetric and time-locked to stimulation of
the VC/VS target (Okun et al., 2004), but may also represent
a positive affective response to the sudden absence of mental
pain (Malone et al., 2009; personal observation). Such an effect
would seem to blur the line between side effect and spontaneous
expression of mood change.
Our observations led us to take a more systematic approach
to intraoperative testing, which confirmed predictable,
reproducible, contact-specific responses in most subjects
(Riva-Posse et al., 2014a). The use of tractography has led us
to optimize electrode placement based on the ability to engage
key white matter tracts within the stimulation zone (Riva-Posse
et al., 2014b). We have observed increased heart rate and skin
conductance with stimulation of appropriately-positioned
contacts, which have greater connectivity to the dorsal anterior
cingulate and subcortical regions (Riva-Posse et al., 2014a).
These autonomic effects are predictable based on the putative
targets of the white matter tracts stimulated, but can tell only
part of the story as additional tracts appear necessary for the
antidepressant response to DBS.
The acute behavioral effects seen with intraoperative
stimulation and described above are typically reproducible
within the immediate post-operative period. In the days
following intraoperative stimulation, it is not uncommon for
our patients to experience some persisting symptom relief
even though stimulation is off. This effect is strongest in
the days after surgery and fades within 3 weeks. Repeating
acute stimulation 1 month after surgery may reproduce the
effects in attenuated form, or they may be absent. These
intraoperative responses are now being evaluated as initial
antidepressant effects, as biomarkers to confirm proper electrode
placement, and as a probe of initial antidepressant physiological
responses.
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TABLE 1 | Emory SCC DBS for depression experience.
Subjects1
• 2080 potential subjects contacted
• 524 completed phone screens
• 274 medical records reviewed
• 76 in-person assessments
• 40 subjects enrolled
 8 failed to meet pre-surgical depression severity criteria2
 1 declined surgery
 1 comorbidity exclusion
• N = 30 implanted
 17 published in Holtzheimer et al. (2012)
 11 manuscript in preparation
 2 in current protocol
Standardized Assessment
• Primary outcome measure: 17 question Hamilton Depression Rating Scale (HDRS-17)
 Response = 50% decrease from baseline; N = 17/30 at one year
 Remission = 7 or less; N = 11/30 at one year
Time Course
• Clinical assessment weekly × 8 months, then tapered to semi-annual assessment by year 2
• 8 years since first subject enrolled
• 1527 subject-months (127 patient-years)
1As of 5/2015, 2HDRS-17 ≥20 averaged over 4 weeks prior to surgery.
Post-Operative Course
A 1-month post-operative recovery period, during which
stimulation is off, is followed by 6 months of continuous
stimulation during which nomedication changes are allowed and
only limited adjustments to stimulation parameters are made.
In our observations, the full antidepressant response evolves
through stereotypic early and late subacute phases before settling
into stable long-term recovery.
Out of the Rut . . .
In the first weeks of chronic stimulation, patients generally
report minimal change, though outside observers notice more
dynamic affect, movement, and speech. Anecdotally, family
members comment that the patient ‘‘looks younger’’ or ‘‘is
more like her old self.’’ Within the first month, patients report
an increase in activity and may notice more things in their
environment. They report little subjective change in mood,
although depression ratings are usually decreasing. Patients
begin to notice that they are having more emotions, including
brief positive moods, before endorsing any significant or lasting
lifting of their depression. Others have similarly observed that
significant subjective improvement in moodmay not be reported
for several weeks of active stimulation (Lozano et al., 2008; Merkl
et al., 2013).
Having chosen the contacts for chronic stimulation on the
basis of tractography and intraoperative effect, we typically do
not make changes to stimulation parameters as this clinical
process unfolds. While it is not uncommon for programming
changes to be required over time in neurodegenerative diseases
like Parkinson’s disease, it is not clear that this level of tuning
is necessary or helpful in depression (Bewernick et al., 2012;
Dougherty et al., 2014). Over time, we have focused on the subtle
signs of improvement, particularly with regard to a patient’s
reactivity. In the absence of a clear biomarker for depression
or DBS treatment effect, it is necessary to rely on clinical
judgment to make such decisions. This task is more difficult in
depression, where a key feature of the illness, negative mood,
is not always pathological nor always attributable to major
depressive disorder. With chronic stimulation, patients learn to
differentiate normal negative emotions from the depressive state.
However, learning to make this distinction and trust one’s ability
to emerge from a sad situation appears to take time and practice
and likely is affected by a patient’s premorbid personality and life
experience.
. . . And Into the Rough Patch
The relatively smooth and progressive improvement in
depressive symptoms seen in the first weeks tends to destabilize
roughly 10–12 weeks after initiation of chronic stimulation.
What follows is a temporary period of subclinical emotional
dysregulation characterized by increased negative affect,
especially flares of anger and irritability, mood swings, and
disproportionate negative emotional reactivity to environmental
stressors. This is often concurrent with increased activity
outside the home and increased frequency and complexity of
interpersonal interactions. This period tends to last around
4 weeks. During this time, patients may report a return of
depressive symptoms with increases in depression rating
scores, although generally they no longer meet criteria for
a major depressive episode. In the Emory experience, these
fluctuations resolve without changes in stimulation parameters.
At a similar time point after starting DBS, Puigdemont et al.
(2012) reported a depressive recurrence in some of their
patients, as well as one suicide attempt. This underscores the
importance of close monitoring of patients during the first
several months of DBS treatment, as this is an expected period
of vulnerability. This phase may also coincide with the timing
of outcome measurements in double-blind controlled clinical
trials (Dougherty et al., 2014), thus confounding a normal
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reemergence of emotional bandwidth with return of true
depressive symptoms as both load onto standard depression
severity scales. Failure to establish clear distinctions between
what appears to be a normal plastic process and the presumed
pathological state has clear implications for evaluating efficacy
and for the design of future trials. In our own studies, once this
stage was recognized, parameter adjustments were halted and
psychotherapy was engaged in earnest.
Recovery Takes More than Stimulation: Chronic
Response and Non-response
After 6 months of chronic stimulation, emotional
hypersensitivity usually abates. Depression rating scale scores
again decrease. Global Assessment of Function scores increase,
as patients become more active and connected with others.
They are able to imagine life further into the future and
entertain longer-term goals, such as a return to employment
or other productive activities. Relationships with loved ones,
especially partners, change in response to the patient’s decreased
dependency. Patients report an increased ability to tolerate
setbacks in life and relationships. We see gradual improvement
in mood and resilience through the first year and beyond,
suggesting ongoing plasticity effects. Long-term follow-up
studies have typically shown that the response at 1 year may
continue to improve in subsequent years (Kennedy et al.,
2011; Holtzheimer et al., 2012). All available evidence suggests
that ongoing stimulation is necessary even in those who have
been in remission for years. With device failure the euthymic
state may hold for a period of time, but usually within weeks
depressive symptoms gradually return. These symptoms are
familiar to patients from previous episodes, although they
rarely have the melancholic features characteristic of the pre-
operative state. When device function is restored, therapeutic
benefit returns, but it may take weeks to fully reach the
previous level of wellness (Kennedy et al., 2011; Merkl et al.,
2013).
Interestingly, even those considered non-responders by study
criteria may nevertheless report meaningful improvement in
their lives and choose to continue the treatment even when
offered discontinuation and device removal, as has been the
experience with other stimulation targets (Bewernick et al., 2010;
Dougherty et al., 2014). In the case of SCC DBS, such a partial
response may be attributable to a failure to stimulate all the
white matter tracts necessary for a full response (Riva-Posse
et al., 2014b). Alternatively, non-response or partial response
may occur as a function of individual disease, biological, or
personality characteristics. It may be that specific depressive
symptom clusters that predominate in an individualmay respond
preferentially to stimulation of one DBS target over another. As
with all psychiatric treatments, personality is bound to play a
role in the nature and timing of therapeutic response or lack
thereof. It is important to note that the core personality traits
of patients who are accepted into DBS studies may be masked
by their chronic depressive illness, such that a full understanding
of their character structure can only be seen after the depressed
state is lifted and the patient returns to previous behavioral
patterns.
Once therapeutic contacts and parameter settings have
been established, they are typically maintained over the years.
Medications are generally not changed significantly once
stimulation is initiated. In some instances, doses have been
reduced, but generally not eliminated. However, since the
protocol does not allow medication changes until after 6
months, it is possible that DBS becomes entrained with the
pharmacological milieu instantiated at the time that DBS effects
evolved. That said, patients do not appear to require medication
to enable a DBS effect as patients on no medications can achieve
clinical response and remission, although this is uncommon.
Discussion
In our experience, patients with the best response to SCC DBS
are those who have a history of treatment-responsive depressive
episodes with good inter-episode recovery, but undergo a
malignant transformation and no longer respond to standard
therapies. The antidepressant response to SCC DBS may be
best described in acute, subacute, and chronic phases. Acute
stimulation of appropriately positioned electrodes is frequently
associated with feelings of relief or increased awareness. These
responses are specific to each individual and highly reproducible
with repeated testing in the intraoperative and perioperative
period.
That said, with chronic stimulation, initial changes are
noticed first by others. Patients notice increased activity
and become more aware of their environment before they
notice improved mood. As patients experience more sustained
improvement in mood and more critically, increased emotional
range, they move from a state of relative stability around a
low negative to relative instability, with heightened emotional
sensitivity and reactivity. Close follow-up and reassurance
during this period of emotional recalibration is warranted,
though frequent stimulation parameter adjustments are not.
This intermediate stage of recovery, generally lasting several
weeks, gives way to increased stability and resilience manifest
by progressive improvement in depressive symptoms that
are maintained over months and years. While the steepest
improvement tends to be seen in the first 6 months, DBS
responders report continued gradual improvement over one or
more years of treatment. Discontinuation of stimulation during
this recovery phase nonetheless leads to a gradual return of
symptoms over several weeks. Current studies are exploring how
rehabilitative strategies may best synergize with these distinct
phases of recovery.
The gradual and predictably bumpy recovery curve in SCC
DBS for depression stands in contrast to the response to DBS
observed in Parkinson’s disease and essential tremor, where
the effect is apparent immediately, maximal effect is reached
within hours, and with discontinuation, primary symptoms
return immediately (Hristova et al., 2000). The response to
DBS for dystonia is more similar to that of depression, as
it develops gradually and maximum effect is seen only after
months of stimulation (Yianni et al., 2003). In dystonia and
depression, neuroplasticity and CNS remodeling may be critical
to the long-term treatment response to DBS (Ruge et al.,
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2011; Gibson et al., 2014). Indeed, changes in serum levels
of brain-derived neurotrophic factor are abnormally low and
increase with antidepressant treatment (Brunoni et al., 2008,
meta-analysis) and in response to chronic DBS in an animal
model (Hamani et al., 2012). DBS-induced plasticity may allow
for changes in regional and network activity that ultimately
result in a normalization of depression-related pathology. PET
scans 3 and 6 months following DBS implantation show activity
changes in depression-relevant regions, including normalization
of hyperactivity in the SCC (Mayberg et al., 2005; Lozano
et al., 2008; Bewernick et al., 2010). Prior to PET scan changes,
autonomic changes accompany the behavioral response to acute
stimulation (Riva-Posse et al., 2014a), and changes in EEG frontal
theta concordance after 1 month of stimulation predict 6 month
response to DBS therapy (Broadway et al., 2012). The time
course varies for different regions, which may reflect both direct
and indirect actions on these networks by acute and chronic
stimulation. Comparable findings have been demonstrated using
EEG, suggesting a differential time course of changes with long-
term stimulation. These findings are consistent with the clinical
observations of phase response characteristics and further they
work toward understanding the mechanism of DBS treatment.
It is hoped that knowledge gained from these small, open-
label, mechanistic investigations will inform the design of
larger scale efficacy trials for DBS. Those who would design
such trials face significant challenges. The heterogeneity of
depression may be obscuring subsets of patients who are
the most appropriate candidates for DBS at each anatomical
target. Inability to effectively quantify the desired patient
characteristics creates a problem for clinical trials, where
everything must be operationalized. Allowances must be made in
treatment decision algorithms for discrepancies between clinical
impression and standardized rating scores. During the transient
period of emotional hypersensitivity in the subacute phase,
depression ratings may worsen, which may trigger protocol-
defined parameter changes that interrupt the natural course
of recovery thus confusing the clinical picture and ultimately,
the demonstration of efficacy. Development of next-generation
closed-loop DBS systems that are capable of monitoring and
responding to changes in neuronal signals may further improve
the conduct of future clinical trials (Afshar et al., 2013; Hosain
et al., 2014; Smart et al., 2015). Such systems will be critical
to identifying biomarkers of DBS-mediated antidepressant
response and hence guide treatment optimization.
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